9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com

12-9213B: Biotinylated Anti-CD160 antibody(DMC270); IgG1 Chimeric mAb

Clonality :	Monoclonal
Clone Name :	DMC270
Application :	Flow Cyt
Reactivity :	Human
Gene :	CD160
Uniprot ID :	O95971
Alternative Name :	BY55; NK1; NK28
Isotype :	IgG1

Description

CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich; glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells; spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16 cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab CD8brightCD95 CD56 CD28-CD27- cells. In tissues; CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.

Product Info

Amount :	10 µg / 100 µg
Purification :	Purified from cell culture supernatant by affinity chromatography
Content :	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage condition :	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Application Note

Flow Cyt 1:100

For Research Use Only. Not for use in diagnostic/therapeutics procedures.